HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Sabine C Herpertz Selected Research

Oxytocin (Pitocin)

1/2022Reduced vagal activity in borderline personality disorder is unaffected by intranasal oxytocin administration, but predicted by the interaction between childhood trauma and attachment insecurity.
1/2020Pain-modulating effects of oxytocin in patients with chronic low back pain.
1/2020Heart and brain: Cortical representation of cardiac signals is disturbed in borderline personality disorder, but unaffected by oxytocin administration.
1/2020Oxytocin and positive couple interaction affect the perception of wound pain in everyday life.
1/2020Oxytocin Normalizes Approach-Avoidance Behavior in Women With Borderline Personality Disorder.
1/2020Oxytocin modulates intrinsic neural activity in patients with chronic low back pain.
10/2019Oxytocin Effects on Pain Perception and Pain Anticipation.
7/2019[Erratum to: Oxytocin and maltreatment potential : Influence of maternal depression, borderline personality disorder and experience of early childhood maltreatment].
3/2019[Oxytocin and maltreatment potential : Influence of maternal depression, borderline personality disorder and experience of early childhood maltreatment].
1/2018Alterations of brain volumes in women with early life maltreatment and their associations with oxytocin.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Sabine C Herpertz Research Topics

Disease

18Borderline Personality Disorder (Personality Disorders, Borderline)
01/2022 - 11/2007
6Hypersensitivity (Allergy)
01/2021 - 10/2013
5Pain (Aches)
01/2020 - 09/2015
4Mental Disorders (Mental Disorder)
01/2021 - 10/2013
4Antisocial Personality Disorder (Antisocial Personality)
01/2018 - 06/2005
3Personality Disorders (Personality Disorder)
09/2020 - 01/2007
3Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder)
01/2017 - 05/2008
2Post-Traumatic Stress Disorders (Post Traumatic Stress Disorder)
09/2022 - 01/2019
2Low Back Pain (Lumbago)
01/2020 - 01/2020
2Asperger Syndrome (Asperger's Syndrome)
02/2014 - 08/2013
2Autism Spectrum Disorder
08/2013 - 03/2007
1Major Depressive Disorder (Major Depressive Disorders)
09/2022
1Medically Unexplained Symptoms
09/2022
1Schizophrenia (Dementia Praecox)
11/2021
1Wounds and Injuries (Trauma)
01/2020
1Chronic Pain
01/2020
1Neurocognitive Disorders (Clerambault Syndrome)
03/2015
1Insulin Resistance
01/2014
1Chronic Disease (Chronic Diseases)
11/2011
1Alzheimer Disease (Alzheimer's Disease)
01/2010
1Hyperkinesis
12/2008
1Conduct Disorder (Conduct Disorders)
04/2007

Drug/Important Bio-Agent (IBA)

21Oxytocin (Pitocin)FDA LinkGeneric
01/2022 - 03/2007
4Hydrocortisone (Cortisol)FDA LinkGeneric
01/2022 - 05/2015
4Biological ProductsIBA
01/2021 - 06/2005
44-aminospiroperidolIBA
01/2018 - 02/2013
2NeuropeptidesIBA
01/2020 - 10/2019
2Methylphenidate (Ritalin)FDA LinkGeneric
01/2017 - 05/2008
2Biomarkers (Surrogate Marker)IBA
03/2015 - 01/2010
1Silver Sulfadiazine (SSD)FDA LinkGeneric
09/2022
1Analgesics (Analgesic Drugs)IBA
01/2020
1Therapeutic UsesIBA
01/2020
1Aminobutyrates (Aminobutyric Acid)IBA
01/2018
1Triiodothyronine (Liothyronine)FDA LinkGeneric
01/2018
1CannabinoidsIBA
09/2015
1Testosterone (Sustanon)FDA Link
05/2015
1Amyloid (Amyloid Fibrils)IBA
03/2015
1LeptinIBA
01/2014
1Antidepressive Agents (Antidepressants)IBA
01/2007
1Pharmaceutical PreparationsIBA
01/2007
1Psychotropic Drugs (Psychoactive Drugs)IBA
01/2007
1Antipsychotic Agents (Antipsychotics)IBA
01/2007

Therapy/Procedure

4Therapeutics
09/2020 - 11/2007
2Transcranial Magnetic Stimulation
12/2008 - 05/2008
1Secondary Prevention
11/2021
1Continuity of Patient Care
11/2021
1Intranasal Administration
10/2013